Inclusion Criteria:

          -  Provision of written informed consent prior to initiation of any study-related
             procedures that are not considered standard of care.

          -  Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of
             informed consent.

          -  ECOG performance status ≤ 2.

          -  Histologically or cytologically confirmed high-grade serous epithelial ovarian
             carcinoma, fallopian tube, or peritoneal carcinoma.

          -  Subjects must have received 1 or 2 prior chemotherapy regimens.

          -  The disease must be platinum-resistant, i.e., the Platinum-Free Interval (PFI) must
             have been < 6 months. Platinum refractory disease, i.e., PD during first-line
             platinum-based therapy is allowed.

          -  Measurable disease per RECIST version 1.1.

          -  Adequate hematologic and organ function as defined by the following criteria:

               1. ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily
                  administration of filgrastim/sargramostim or within 3 weeks after administration
                  of pegfilgrastim.

               2. Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days
                  after transfusion of platelets.

               3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper
                  limit of normal (ULN). If liver function abnormalities are due to underlying
                  liver metastases, AST and ALT ≤ 5 x ULN.

               4. Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.

               5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.

          -  Female subjects of childbearing potential must have a negative serum beta human
             chorionic gonadotropin (β-hCG) test and agree to use an effective method of
             contraception per institutional standard.

          -  Left ventricular ejection fraction (LVEF) ≥ 50% or within normal limits of the
             institution (only for subjects treated with PLD).

        Exclusion Criteria:

          -  Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline
             ovarian tumor.

          -  Any of the following treatment interventions within the specified time frame prior to
             Cycle 1 Day 1:

               1. Major surgery within 28 days.

               2. Radiation therapy within 21 days.

               3. Autologous or allogeneic stem cell transplant within 3 months.

          -  A serious illness or medical condition(s) including, but not limited to, the
             following:

               1. Brain metastases that require immediate treatment or are clinically or
                  radiologically unstable.

               2. Leptomeningeal disease that requires or is anticipated to require immediate
                  treatment.

               3. Myocardial impairment of any cause.

               4. Significant gastrointestinal abnormalities.

               5. Active or uncontrolled infection.

          -  Unresolved toxicity of Grade > 1 attributed to any prior therapies (excluding Grade 2
             neuropathy, alopecia or skin pigmentation).

          -  Pregnant or lactating females (including the cessation of lactation) or females of
             childbearing potential who have a positive serum pregnancy test within 14 days prior
             to Cycle 1 Day 1.

          -  Subjects with active (uncontrolled, metastatic) second malignancies or requiring
             therapy.

          -  12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of
             > 450 msec, except for subjects with atrioventricular pacemakers or other conditions
             (e.g., right bundle branch block) that render the QT measurement invalid.

          -  History or current evidence of congenital long QT syndrome.

          -  Taking medications that lead to significant QT prolongation.

          -  Administration of strong and moderate CYP3A4 inhibitors and inducers as well as strong
             and moderate P-glycoprotein (P-gp) inhibitors.